Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

DOJ seeks dismissal of corruption charges against billionaire Gautam Adani

Published

on

DOJ seeks dismissal of corruption charges against billionaire Gautam Adani

The U.S. Department of Justice has formally asked a federal court to dismiss criminal charges against Gautam Adani, an Indian billionaire accused of misleading U.S. and global investors while raising billions of dollars to finance a major solar energy project in India.

Adani, considered one of Asia’s richest individuals, allegedly promised to pay more than $250 million in bribes to Indian officials to secure lucrative contracts. He and his executives further raised money from investors by falsely claiming the company maintained strict anti-corruption policies — all while allegedly continuing the bribery scheme and later attempting to conceal the evidence, prosecutors alleged in 2024.

Advertisement

Despite the severity of the allegations, the Justice Department has requested the case be dismissed “with prejudice,” indicating that the charges would be permanently dropped and may not be brought again in the future, according to court records filed Monday. Adani Group has denied the allegations, calling them baseless.

“The Department of Justice has reviewed this case and has decided, in its prosecutorial discretion, not to devote further resources to these criminal charges against individual defendants,” prosecutors wrote in a court filing.

INDIA BILLIONAIRE SCANDAL A ‘HITJOB’ BY US FIRM ATTACKING FINANCIAL SYSTEMS, SUPPORTERS CLAIM

Gautam Adani having conversation during an all-party prayer meeting

Gautam Adani has a conversation during an all-party prayer meeting on February 23, 2026, in Mumbai, India.  (Bhushan Koyande/Hindustan Times via Getty Images / Getty Images)

The decision to drop the charges follows an announcement from the U.S. Securities and Exchange Commission (SEC) that it moved for entry of final judgments by consent, subject to court approval, in a related lawsuit involving Adani. The proposed resolution would not require Gautam Adani or Sagar Adani to admit or deny the SEC’s allegations.

Advertisement

Beginning in 2020, Adani Green Energy Limited, led by Gautam Adani, secured a major contract to develop solar power projects in India.

However, some Indian state governments allegedly declined to purchase the electricity from the project due to high costs. 

Gautam Adani portrays a prayer stance during a festival

Gautam Adani, chairman of Adani Group, attends a festival in Prayagraj, Uttar Pradesh, India, on Tuesday, Jan. 21, 2025.  (Indranil Aditya/Bloomberg / Getty Images)

As a result, Gautam Adani and his nephew, Sagar Adani, allegedly resorted to bribery, including promises of more than $250 million in payments to Indian officials, in order to secure power purchase agreements for the expensive solar energy.

BILLIONAIRE INVESTOR ISSUES WARNING OVER CHINA’S ‘CRAZY’ BUSINESS TACTIC: BE ‘VERY CAREFUL’

Advertisement
Ticker Security Last Change Change %
ADANIGREEN NO DATA AVAILABLE

During the same period, the company required significant capital to finance the projects and raised approximately $750 million through bond sales to U.S. and global investors. 

Federal prosecutors alleged that Adani Green and related entities raised more than $3 billion through loans and bond offerings while making false and misleading statements about the company’s anti-bribery and anti-corruption practices.

Prosecutors added that, to attract investors, the company falsely portrayed itself as an industry leader in corporate governance with a strict “zero tolerance” policy on bribery.

Adani billiionaire controversy

Indian billionaire Gautam Adani speaks during an interview at his office in the western Indian city of Ahmedabad on April 2, 2014. (Reuters/Amit Dave/File Photo/File Photo / Reuters Photos)

When U.S. authorities, including the FBI and the SEC, began investigating the alleged corruption, several executives were accused by prosecutors of attempting to obstruct the inquiry by deleting emails and electronic messages, concealing information during internal investigations, and making false statements to federal agents.

Advertisement

CLICK HERE TO GET THE FOX BUSINESS APP

The case dismissal is contingent upon approval by Judge Nicholas Garaufis, according to the documents. 

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Thai Navy Seizes Over 6 Million Meth Pills During Border Operation in Chiang Rai

Published

on

Thai Navy Seizes Over 6 Million Meth Pills During Border Operation in Chiang Rai

The Royal Thai Navy seized over six million methamphetamine tablets smuggled across the Mekong River, highlighting ongoing efforts against transnational drug trafficking despite the escape of the perpetrators.


Key Points

  • The Royal Thai Navy seized over six million methamphetamine tablets smuggled across the northern border along the Mekong River, following intelligence about narcotics trafficking into Thailand.
  • During operations near Thai Charoen Village, officers observed a boat from a neighboring country discarding 17 sacks of methamphetamine marked with the Y1 stamp before fleeing. Law enforcement secured the evidence for further investigation.

The Royal Thai Navy announced the seizure of over six million methamphetamine tablets smuggled across the northern border along the Mekong River.

​Royal Thai Navy Spokesperson Rear Admiral Paraj Ratanajaipan stated that the Mekong Riverine Unit received intelligence about an attempt to smuggle narcotics into the kingdom. The cargo was tracked to riverbanks near Thai Charoen Village in Wiang Kaen District, Chiang Rai Province, and operational forces were promptly deployed to monitor the area.

​During the operation, officers observed a boat from a neighboring country docked along the Mekong River bank. Items were thrown ashore before the boat quickly departed. Officers, together with local security and administrative agencies, then inspected the area.

​The inspection uncovered 17 sacks containing Category 1 narcotics, specifically methamphetamine pills marked with the Y1 stamp. Although the perpetrators escaped across the border, law enforcement secured the contraband and collected forensic evidence. The seized narcotics were transferred to investigators at the Wiang Kaen Provincial Police Station for further legal action.

Advertisement

​The spokesperson noted that this seizure demonstrates how transnational trafficking syndicates exploit border rivers to transport illicit drugs into Thailand. He emphasized that the Royal Thai Navy and allied security agencies remain fully coordinated, enforcing strict border surveillance and legal measures to dismantle trafficking routes, safeguard national security, and protect the public.

Source : Thai Navy Seizes Over 6 Million Meth Pills During Border Operation in Chiang Rai

Continue Reading

Advertisement
Continue Reading

Business

Form 4 Pvh For: 17 June

Published

on


Form 4 Pvh For: 17 June

Continue Reading

Business

Slideshow: Entrepreneurs enhancing protein

Published

on

Slideshow: Entrepreneurs enhancing protein

Introductions include protein-centered offerings, alternative ingredient formulations and globally-inspired products.

Continue Reading

Business

Gold Prices Rise 0.58% to $4,379.50 as Safe-Haven Demand Persists Amid Economic Uncertainty

Published

on

Gold and silver bars

Gold prices climbed Wednesday, with spot gold reaching $4,379.50 per ounce, up $25.10 or 0.58 percent, as investors sought refuge in the precious metal amid ongoing geopolitical tensions, inflation concerns and uncertainty around Federal Reserve policy.

The gain follows a period of volatility in 2026, during which gold hit record highs above $5,500 per ounce earlier in the year before pulling back sharply. Wednesday’s advance reflects renewed safe-haven buying as markets digest mixed economic signals and potential shifts in monetary policy under the new Fed leadership.

Gold has served as a traditional hedge against inflation, currency fluctuations and geopolitical risks. Central bank purchases have provided strong structural support, with many institutions continuing to diversify reserves away from traditional holdings. Emerging market buyers in particular have driven demand, contributing to sustained interest even after the early-year peak.

Market Drivers and Recent Performance

Advertisement

Analysts attribute the latest uptick to several factors. Expectations around the Federal Reserve’s June meeting, chaired by Kevin Warsh, have kept markets cautious. Stronger-than-expected U.S. jobs data in recent weeks have tempered hopes for imminent rate cuts, boosting the dollar at times but also highlighting persistent inflation risks that favor gold.

Geopolitical developments, including Middle East dynamics and broader global tensions, have reinforced gold’s appeal. Investors view the metal as a reliable store of value when traditional assets face pressure. Central banks worldwide have signaled continued accumulation, with surveys showing record intent to increase gold reserves.

Year-to-date, gold has experienced significant swings. After surging to all-time highs in January, prices corrected by more than 20 percent at points, testing support levels near $4,100-$4,300. The current level around $4,379 represents a partial recovery, with analysts watching for sustained momentum above key technical thresholds.

Silver prices also moved higher in tandem, reflecting broader precious metals demand. Industrial uses for silver in electronics and renewable energy sectors have complemented investment flows.

Advertisement

Central Bank Role and Long-Term Outlook

Central bank buying remains a dominant theme. The World Gold Council and other reports indicate robust demand from institutions seeking diversification. Projections from major banks like J.P. Morgan suggest gold could push toward $6,000 per ounce by year-end under supportive scenarios involving persistent inflation and geopolitical risks.

This outlook aligns with broader forecasts. Goldman Sachs and others anticipate continued upward pressure into 2026 and beyond, driven by structural shifts in global reserves and investor portfolios. However, near-term volatility persists, with some analysts warning of potential consolidation if U.S. economic data strengthens further.

Physical demand in major markets like India and China has shown resilience, though seasonal factors and price sensitivity influence retail buying patterns. Exchange-traded funds tracking gold have seen mixed flows, with some outflows during the correction phase followed by renewed interest.

Advertisement

Investment Implications

For investors, gold offers portfolio diversification benefits. Its low correlation with stocks and bonds makes it attractive during periods of market stress. Financial advisors often recommend allocations of 5-10 percent in precious metals as a hedge, particularly for those concerned about long-term inflation or currency devaluation.

Retail investors can access gold through physical bullion, coins, ETFs or mining stocks. Recent price action has drawn attention from both long-term holders and tactical traders. Options and futures markets show active positioning around current levels.

Challenges include opportunity costs when interest rates remain elevated, as non-yielding gold competes with interest-bearing assets. Storage and insurance costs for physical holdings also factor into decisions. Despite these, many view current valuations as reasonable following the pullback from peaks.

Advertisement

Broader Economic Context

Gold’s performance intersects with several macroeconomic trends. Government debt levels globally have risen, prompting some investors to favor hard assets. Currency dynamics, including periods of dollar weakness, have historically supported higher gold prices.

Inflation readings remain a focal point. Recent CPI data has shown stickiness above targets in some categories, reinforcing gold’s role as an inflation hedge. Meanwhile, fiscal policy debates and potential stimulus measures could further influence investor sentiment.

The mining sector has responded to price movements, with producers benefiting from higher realizations while managing cost pressures. Exploration and development projects continue, though regulatory and environmental considerations add complexity.

Advertisement

Technical Outlook

From a charting perspective, gold has found support in the $4,300 area after testing lower levels. Resistance sits near recent highs around $4,500-$4,600. Analysts monitor moving averages and key Fibonacci retracement levels for clues on next moves. A break above $4,500 could signal renewed bullish momentum, while a drop below $4,300 might test lower supports.

Volume and open interest in futures contracts provide additional insights. Wednesday’s trading showed solid participation, consistent with ongoing interest in the metal.

Risks and Considerations

Advertisement

While the long-term case for gold remains constructive for many, risks abound. Stronger U.S. growth could support the dollar and pressure gold. Faster disinflation might accelerate rate cut expectations in ways that temporarily weigh on the metal. Geopolitical de-escalation could also reduce safe-haven flows.

Investors are advised to maintain diversified approaches and avoid over-concentration. Dollar-cost averaging into positions can help manage volatility. Professional guidance is recommended for those new to commodity investments.

As markets evolve, gold’s role as a strategic asset endures. Wednesday’s modest gain to $4,379.50 underscores its resilience even after a corrective phase. With central bank support and macroeconomic uncertainties in play, the metal is likely to remain in focus for investors seeking stability in an unpredictable global environment.

Looking ahead, key events such as further Fed communications, inflation reports and international developments will shape price direction. For now, the yellow metal continues to attract attention as both a tactical trade and a long-term holding in uncertain times.

Advertisement
Continue Reading

Business

Expeditors International of Washington, Inc. (EXPD) Discusses U.S. Customs Market Update With Focus on Current Tariff Updates and Trade Actions Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Nicole Gallanis

Hello, everyone, and welcome to our U.S. Customs Market Update webinar. Thank you for joining us today. We are going to go through a U.S. customs market update with our team. And before we start, we’re going to go through a few ground rules and just how the webinar will run and cover some questions that we often get, and then we’ll hand it over to our experts to go through the content.

And then finally, end if we have some time with some question and answer, normally, we go right to the end. So if we don’t cover your question today, we will certainly follow up after the webinar. My name is Nicole Gallanis. I’m new or I’m covering for Samantha, who you normally see on these webinars today.

So she is out on vacation. So if you do have any questions or don’t receive the survey after the webinar, that’s usually how we will distribute the content to you. So if you don’t receive that, you can certainly reach out to me, and I will make sure that you get a copy of the materials that we shared. If you are hearing an echo, you might have — you might be joined on multiple devices.

Advertisement

So please make sure that you are only joined from your one device. We often get that feedback as well. And if you do have any questions, please put those into the Q&A window at the bottom of your screen. Our team

Continue Reading

Business

Import-Price Inflation Remained Firm in May

Published

on

Import-Price Inflation Remained Firm in May

Prices on U.S. energy imports rose at a slower rate last month as the global economy adjusted to the effects of the Iran conflict, but overall growth in import prices remained elevated, the Labor Department reported Tuesday.

Prices paid for fuel imports climbed by 12.5% in May, after rising by 18.6% in April. On nonpetroleum imports, prices grew by 0.8% last month, versus April’s 0.6% increase.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue Reading

Business

Morgan Stanley A Vs. E Preferred Shares: Ratings Remain Unchanged

Published

on

Morgan Stanley A Vs. E Preferred Shares: Ratings Remain Unchanged

Morgan Stanley A Vs. E Preferred Shares: Ratings Remain Unchanged

Continue Reading

Business

After-Hours Stock Movers: SWBI, SB, LPA, STLD, SPCX

Published

on


After-Hours Stock Movers: SWBI, SB, LPA, STLD, SPCX

Continue Reading

Business

Huntington’s disease drugmaker UniQure to seek FDA OK for gene therapy

Published

on

FDA official discusses UniQure gene therapy for Huntington's disease

Thomas Fuller | SOPA Images | Lightrocket | Getty Images

UniQure plans to seek FDA approval of its experimental gene therapy for Huntington’s disease, the company said Wednesday, months after previous agency leaders criticized the evidence backing the application.

UniQure said the FDA in a recent meeting communicated that a three-year analysis from a Phase 1/2 study would support an accelerated approval of UniQure’s gene therapy for Huntington’s, a rare hereditary disease that gradually destroys nerve cells in the brain. As a result of the meeting, UniQure plans to submit its application to the FDA in the third quarter of this year.

Advertisement

An FDA official confirmed that the agency and the company have agreed on a path for submission for a marketing application and accelerated approval of the therapy based on the existing clinical data. The FDA “remains committed to working with UniQure to identify a regulatory pathway that serves patients with Huntington’s disease and their families, while upholding the agency’s commitment to gold-standard science,” the official said in a statement.

Shares of UniQure soared 70% on Wednesday.

The new FDA guidance represents a stunning reversal from March, when the regulator told Uniqure that its clinical trial data wouldn’t support an application and publicly criticized the company. UniQure became a prime example in a series of reversals where companies said the FDA had changed its previous guidance, hitting rare disease drugmakers especially hard. Many of those decisions happened under former FDA Commissioner Marty Makary, who left the agency in May.

In a February interview with CNBC’s Becky Quick, then-Commissioner Makary described UniQure’s treatment without naming it, saying the agency was pressured to approve it even though it showed “no benefit.” Then UniQure said the FDA couldn’t agree that data from a clinical trial comparing UniQure’s gene therapy to an external control are sufficient to support an application.

Advertisement

A senior FDA official at the time confirmed to reporters that the FDA wanted UniQure to run a placebo-controlled trial to prove its therapy “actually helps people.” The gene therapy is administered directly into the brain through an hours-long surgery, and UniQure has said it would be unethical to make people undergo a sham procedure.

Huntington’s disease, also known as Huntington’s chorea, is a neurodegenerative disease due to a mutation in the huntingtin gene, HTT.

Kateryna Kon/science Photo Library | Science Photo Library | Getty Images

Instead, the company compared the progression of people who received the treatment to the typical progression of Huntington’s disease using an outside database. Using that approach, UniQure’s gene therapy slowed disease progression by 75% in a Phase 1/2 trial.

Advertisement

With the FDA’s blessing, UniQure now plans to use the same data that came under scrutiny to support its application. An accelerated approval would allow UniQure’s treatment to come to market on the condition that the company prove the benefit in another study.

UniQure on Wednesday said the FDA wants to align on that study’s design, including comparing the treatment to the current standard of care rather than a sham procedure. UniQure said it’s committed to conducting that study and expects to finalize those plans before submitting its application.

UniQure isn’t the only company to see its fortunes reverse following the departure of Makary and other senior leaders, including former Center for Biologics Evaluation and Research director Vinay Prasad and former Center for Drug Evaluation and Research director Tracy Beth Høeg. Replimune recently announced it would seek approval of its experimental melanoma drug for a third time.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Advertisement
Continue Reading

Business

UK inflation holds steady at 2.8% as food price rises ease

Published

on

Business Live

It was lower than economists expected

A view of the Bank of England

A view of the Bank of England(Image: PA Archive/PA Images)

Inflation has remained below three per cent, though economists are forecasting further price rises later in the year.

Advertisement

The Office for National Statistics revealed that inflation in the 12 months to May came in lower than analysts had anticipated, with the consumer prices index (CPI) recording a figure of 2.8 per cent.

Core inflation, which excludes volatile energy and food prices, stood at 2.6 per cent, while services inflation — closely watched by Bank of England rate-setters for signs of wage pressures — rose sharply from 3.2 per cent to 3.7 per cent.

“The main upward movement came from transport with airfares, vehicle taxes and petrol prices all pushing up inflation,” Grant Fitzner, chief economist at the ONS, said.

“These were offset by lower food prices, with decreases in inflation seen across a range of meat, dairy and vegetable items compared to last month as well as the cost of domestic heating oil, which fell back after climbing in recent months.”

Advertisement

Analysts have suggested inflation could approach four per cent later this year and into early 2027, with the Bank warning that prices could surge as high as six per cent in the most severe scenario, as reported by City AM.

Much of what happens next hinges on whether the Strait of Hormuz fully reopens following the peace agreement between the US and Iran, as well as how businesses respond to the shifting economic landscape.

Paul Dales, chief UK economist at Capital Economics, forecast that inflation would climb over the coming nine months, though a recent dip in oil prices suggests it may fall short of four per cent.

He noted that recent data indicated higher energy costs “don’t yet seem to be feeding into other items”, as evidenced by easing food price inflation.

Advertisement

Andrew Griffith, the shadow business secretary, cautioned that rising business costs of as much as nine per cent “means either higher prices are coming to the high street, more firms closing with the loss of jobs, or both”.

Should tensions flare up once more across the Middle East, analysts caution that upward pressure on prices could intensify.

The Bank’s Monetary Policy Committee faces a considerable challenge given a weakening labour market and stubbornly elevated inflation expectations.

Luke Bartholomew, deputy chief economist at Aberdeen, said: “With inflation coming in softer than expected again, the pressure on the Bank of England to hike rates this year will continue to fade, although there may still be a couple of policymakers who vote for a rate increase tomorrow.

Advertisement

“Despite energy prices having fallen recently, there is more inflationary pressure to come for the UK.”

The Bank is expected to lean on its scenario modelling, with two outcomes from the Iran conflict suggesting that interest rates would not need to rise. In the worst-case scenario, however, interest rates could surge back to their previous peak of 5.25 per cent.

This would largely be driven by “second round effects”, where high wage pressures spill into higher prices for consumers, and vice-versa.

Economists on City AM’s Shadow MPC called on the Bank to hold interest rates steady, warning that overly aggressive tightening could risk strangling economic growth, while evidence of mounting wage growth pressures remained inconclusive.

Advertisement

Two out of nine economists on the Shadow MPC argued that interest rates should be raised, citing the price risks facing the UK economy in the months ahead.

Economists also cautioned that the Bank faces a significant challenge in maintaining public credibility over its capacity to keep prices stable should inflation climb higher than anticipated.

Rachel Reeves said: “While the war in the Middle East pushes prices up globally, we have got the right economic plan and inflation has held steady.”

Advertisement
Continue Reading

Trending

Copyright © 2025